ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GRPH Graphene Nano

1.93
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Graphene Nano LSE:GRPH London Ordinary Share GB00B9BBJ076 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.93 1.86 2.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Graphene Nano Share Discussion Threads

Showing 8351 to 8367 of 8600 messages
Chat Pages: 344  343  342  341  340  339  338  337  336  335  334  333  Older
DateSubjectAuthorDiscuss
09/10/2017
12:01
20% spread LOL!
telbap
09/10/2017
11:53
Once the debt re-structuring is confirmed....The share price here will Rally significantly, tie that in with some contract details and from this lowly price we should have ourselves a multi-bagger..
the egregore
09/10/2017
11:08
Unusual tight spread online 1.28-1.305p
dave4545
09/10/2017
08:27
Sp looking like its ready to take off in expectation of confirmation of Debt re-structuring completion RNS and Contract news...
the egregore
08/10/2017
12:52
[...]

Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS)
By Alliance | Fri, 6th October 2017 - 14:19

LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company.
The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin.
Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo.
The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%.
Merrill Lynch had a holding that was below the notable threshold prior to the purchase.
Motif Bio shares were up 6% on Friday at 46.11 pence.
By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance

Read more:

A step ahead of ImmuPharma is Motif Bio, which has successfully completed not one, but two phase III clinical trials and is preparing to submit its antibiotic, iclaprim, for regulatory sign-off. While the shares are up 23 per cent this week at around 43p, analysts think it could be worth double that figure.
Amphion Innovations, the investment group, owns just over 14 per cent of Motif. Its chief executive thinks market hasn’t quite grasped how valuable this shareholding is. He might be right as Amphion’s market capitalisation is some way short of the value of its Motif investment

cool druid
07/10/2017
18:28
Rather downbeat assessment of GPRH's prospects.
obbig60
07/10/2017
15:18
#GRPH HEADLINE FT RECOVERY STOCK Small-cap focus: # Graphene Nanochem😉
dice1950
06/10/2017
21:33
Leedskier seems quiet these days? It appears this dog of a company is still going one direction and the only losers are the PI’s. Wonder what patents they have registered and in who’s name?
roddyb
03/10/2017
22:32
Blatent attemps by MMs trying hard to suck in PIs with crazy hikes in the price only to keep the spread at 40%!
telbap
02/10/2017
17:27
And down we go.....
telbap
30/9/2017
08:48
Blue7
That has been on their website for at least two years, all part of the deceit and or incompetence . . . . . Not many straws left to grab, if any . . . . .

1sillydoris
29/9/2017
11:51
Sold out after results. Managed to get some 1.08p last week so managed to make a few quid out of them.
dave4545
29/9/2017
07:44
Only hot if the first half year figures get released today.
mdvorkin
29/9/2017
07:34
Interesting strategy Egregore. Good luck....
bernieboy
28/9/2017
21:29
Blueshoes>>>;>> I have over 900k of these now at an average of 1.37p. I bought Tuesday, Yesterday and Today. Years ago i held a similar stock bought at 0.55p over 3 million of them.. Total cost was approx £17 K ish.. Loveless and looking like they were going bust. Very similar to this, different market place (mining) .. One small bit of news in that case it was sale of some ore and more to follow...Two days the high was 11p, i sold all the way up..Made over £200k...

My criteria is simple and these fit. (1) Limited Shares in issue (Tick just 200 mill) (2) Priced to go Bust (Tick)(3) Company has at the bare minimum something to sell (tick)(4) Majority of shares i.e. 60% or more held by 1 or more major holders (tick) (5) Assured that on the sniff of positive news the Swarm will hit these like locust looking to buy in (Tick).

Far as I'm concerned these are currently Very Hot Property..yet few realise it..We will now wait and see...I will continue to suck a few more up sub 1.6p..

the egregore
28/9/2017
13:47
Well Done... Volume will pick up this afternoon....
blueshoes7
28/9/2017
13:41
Just bought another two tranches 150k and 167 k.. Will continue to accumulate..
the egregore
Chat Pages: 344  343  342  341  340  339  338  337  336  335  334  333  Older

Your Recent History

Delayed Upgrade Clock